Previous 10 | Next 10 |
FOSTER CITY, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including o...
The following slide deck was published by Terns Pharmaceuticals, Inc. in conjunction with this event. For further details see: Terns Pharma (TERN) Investor Presentation - Slideshow
InvestorPlace - Stock Market News, Stock Advice & Trading Tips The stock market got crushed in 2022. It was a nasty year for most investors. But what if I told you that amid 2022’s financial market turmoil, there was a quantitative trading system that was regularly pi...
FOSTER CITY, Calif., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including o...
Plans to advance diverse pipeline of five disclosed programs in oncology and metabolic diseases Expects to initiate proof of concept trials in CML and obesity and to report top-line data from DUET, the first trial assessing THR-β agonist as monotherapy and in combination with FXR...
FOSTER CITY, Calif., Dec. 23, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including o...
Biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis, Terns Pharmaceuticals ( NASDAQ: TERN ) prices its underwritten public offering of 10.35M shares a...
FOSTER CITY, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including o...
FOSTER CITY, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including o...
Terns Pharmaceuticals ( NASDAQ: TERN ) has commenced a proposed underwritten public offering of $75M of shares of its common stock. In addition, the company expects to grant the underwriters a 30-day option to purchase additional shares. Actual size and terms of the offering a...
News, Short Squeeze, Breakout and More Instantly...
Terns Pharmaceuticals Inc. Company Name:
TERN Stock Symbol:
NASDAQ Market:
Terns Pharmaceuticals Inc. Website:
2024-07-20 09:30:00 ET Eli Lilly and Novo Nordisk are, for now, the undisputed champions of the market for weight-loss medicines. Thanks to the outrageous popularity of Lilly's drug Zepbound and Novo's product Wegovy, the biggest contest of the moment will go to whoever can ramp up ...
2024-07-17 00:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
FOSTER CITY, Calif., June 21, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including o...